KantoffPW, HiganoCS, ShoreNDet al.Sipuleucel-T immunotherapy for castration-resistant prostate cancer. New Engl J Med, 2010; 363:411.
2.
HiganoCS, SchellhammerPF, SmallEJet al.Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer. Cancer, 2009; 115:3670.
3.
KantoffPW, SchuetzTJ, BlumensteinBAet al.Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol, 2010; 28:1099.
4.
SchusterSJ, NeelapuSS, GauseBLet al.Vaccination with patient-specific tumor-derived antigen in first remission improves disease-free survival in follicular lymphoma. J Clin Oncol, 2011; 29:2787.
5.
FreedmanA, NeelapuSS, NicholsCet al.Placebo-controlled phase III trial of patient-specific immunotherapy with mitumprotimut-T and granulocyte-macrophage colony-stimulating factor after rituximab in patients with follicular lymphoma. J Clin Oncol, 2009; 27:3036.
6.
SchwartzentruberDJ, LawsonDH, RichardsJMet al.gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med, 2011; 364:2119.
7.
ButtsC, MurrayN, MaksymiukAet al.Randomized phase IIB trial of BLP25 liposome vaccine in stage IIIB and IV non-small-cell lung cancer. J Clin Oncol, 2005; 23:6674.
8.
MellstedtH, VansteenkisteJ, ThatcherN. Vaccines for the treatment of non-small cell lung cancer: Investigational approaches and clinical experience. Lung Cancer, 2011; 73:11.
9.
NemunaitisJ, NemunaitisM, SenzerNet al.Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non-small cell lung cancer (NSCLC) patients. Cancer Gene Ther, 2009; 16:620.
10.
VansteenkisteJ, ZielinskiH, LinderAet al.Final results of a muilti-center, double-blind, randomized, placebo-controlled Phase II study to assess the efficacy of MAGE-A3 immunotherapeutic as adjuvant therapy in stage Ib/II non-small cell lung cancer (NCSLC) [abst]J Clin Oncol, 2007; 25,suppl18.
11.
GulleyJL, ArlenPM, MadanRAet al.Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother, 2010; 59:663.
12.
SteinWD, GulleyJL, SchlomJet al.Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: The growth rate constant as an indicator of therapeutic efficacy. Clin Cancer Res, 2011; 17:907.
13.
von MehrenM, ArlenP, GulleyJet al.The influence of granulocyte macrophage colony-stimulating factor and prior chemotherapy on the immunological response to a vaccine (ALVAC-CEA B7.1) in patients with metastatic carcinoma. Clin Cancer Res, 2001; 7:1181.
14.
von MehrenM, ArlenP, TsangKYet al.Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin Cancer Res, 2000; 6:2219.
15.
Docetaxel and prednisone with or without vaccine therapy in treating patients with metastatic hormone-resistant prostate cancer. www.clinicaltrials.gov/ct2/show/NCT01145508?term=McNeel&rank=5. 2011 December 26.
16.
BristolJA, SchlomJ, AbramsSI. Persistence, immune specificity, and functional ability of murine mutant ras epitope-specific CD4(+) and CD8(+) T lymphocytes following in vivo adoptive transfer. Cell Immunol, 1999; 194:78.
17.
HodiFS, O'DaySJ, McDermottDFet al.Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med, 2010; 363:711.
18.
BrahmerJR, DrakeCG, WollnerIet al.Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol, 2010; 28:3167.
19.
KlineJ, GajewskiTF. Clinical development of mAbs to block the PD1 pathway as an immunotherapy for cancer. Curr Opin Investig Drugs, 2010; 11:1354.
20.
ChakrabortyM, SchlomJ, HodgeJW. The combined activation of positive costimulatory signals with modulation of a negative costimulatory signal for the enhancement of vaccine-mediated T-cell responses. Cancer Immunol Immunother, 2007; 56:1471.
21.
MadanRA, MohebtashM, ArlenPMet al.A phase I trial of ipilimumab and a poxviral vaccine targeting PSA in metastatic castration-resistant prostate cancer: analysis of toxicity, response, and survival. Lancet OncolAccepted for publication.
22.
van den EertweghAJM, VersluisJ, van den BergHPet al.A phase I trial of combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells (GVAX) and ipilimumab in patients with metastatic castration-resistant prostate cancer. Lancet OncolAccepted for publication.
23.
CarmelietP, JainRK. Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov, 2011; 10:417.
GajewskiTF. Failure at the effector phase: Immune barriers at the level of the melanoma tumor microenvironment. Clin Cancer Res, 2007; 13:5256.
26.
GajewskiTF, MengY, BlankCet al.Immune resistance orchestrated by the tumor microenvironment. Immunol Rev, 2006; 213:131.
27.
GajewskiTF, MengY, HarlinH. Immune suppression in the tumor microenvironment. J Immunother, 2006; 29:233.
28.
KeppO, GalluzziL, MartinsIet al.Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev, 2011; 30:61.
29.
TesniereA, SchlemmerF, BoigeVet al.Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene, 2010; 29:482.
30.
ZitvogelL, KeppO, SenovillaLet al.Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res, 2010; 16:3100.
31.
ChakrabortyM, AbramsSI, ColemanCNet al.External beam radiation of tumors alters phenotype of tumor cells to render them susceptible to vaccine-mediated T-cell killing. Cancer Res, 2004; 64:4328.
32.
GarnettCT, SchlomJ, HodgeJW. Combination of docetaxel and recombinant vaccine enhances T-cell responses and antitumor activity: Effects of docetaxel on immune enhancement. Clin Cancer Res, 2008; 14:3536.
33.
GelbardA, GarnettCT, AbramsSIet al.Combination chemotherapy and radiation of human squamous cell carcinoma of the head and neck augments CTL-mediated lysis. Clin Cancer Res, 2006; 12:1897.
34.
EmensLA, AsquithJM, LeathermanJMet al.Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol, 2009; 27:5911.
35.
GameiroSR, CaballeroJA, HigginsJPet al.Exploitation of differential homeostatic proliferation of T-cell subsets following chemotherapy to enhance the efficacy of vaccine-mediated antitumor responses. Cancer Immunol Immunother, 2011; 60:1227–1242.
36.
FarsaciB, HigginsJP, HodgeJW. Consequence of dose scheduling of sunitinib on host immune response elements and vaccine combination therapy. Int J Cancer, 2011Jun1E-pub ahead of print.
37.
FarsaciB, SabzevariH, HigginsJPet al.Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine. Int J Cancer, 2010; 127:1603.
38.
FinkeJH, RiniB, IrelandJet al.Sunitinib reverses type-1 immune suppression and decreases T-regulatory cells in renal cell carcinoma patients. Clin Cancer Res, 2008; 14:6674.
39.
KoJS, ZeaAH, RiniBIet al.Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients. Clin Cancer Res, 2009; 15:2148.
40.
ArredouaniMS, Tseng-RogenskiSS, HollenbeckBKet al.Androgen ablation augments human HLA2.1-restricted T cell responses to PSA self-antigen in transgenic mice. Prostate, 2010; 70:1002.
41.
LeeDK, HakimFT, GressRE. The thymus and the immune system: Layered levels of control. J Thorac Oncol, 2010; 5:S273.
42.
MercaderM, BodnerBK, MoserMTet al.T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A, 2001; 98:14565.
43.
BilusicM, GulleyJ, HeeryCet al.A randomized phase II study of flutamide with or without PSA-TRICOM in nonmetastatic castration-resistant prostate cancer [abst]J Clin Oncol, 2011; 29,suppl7.
44.
MadanRA, GulleyJL, SchlomJet al.Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy. Clin Cancer Res, 2008; 14:4526.
45.
SandaMG, SmithDC, CharlesLGet al.Recombinant vaccinia-PSA (PROSTVAC) can induce a prostate-specific immune response in androgen-modulated human prostate cancer. Urology, 1999; 53:260.
46.
DhodapkarKM, FeldmanD, MatthewsPet al.Natural immunity to pluripotency antigen OCT4 in humans. Proc Natl Acad Sci U S A, 2010; 107:8718.
47.
FernandoRI, LitzingerM, TronoPet al.The T-box transcription factor Brachyury promotes epithelial-mesenchymal transition in human tumor cells. J Clin Invest, 2010; 120:533.
48.
HuaW, YaoY, ChuYet al.The CD133+ tumor stem-like cell-associated antigen may elicit highly intense immune responses against human malignant glioma. J Neurooncol, 2011Apr11E-pub ahead of print.
49.
MineT, MatsuedaS, LiYet al.Breast cancer cells expressing stem cell markers CD44+ CD24 lo are eliminated by Numb-1 peptide-activated T cells. Cancer Immunol Immunother, 2009; 58:1185.
50.
PalenaC, PolevDE, TsangKYet al.The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res, 2007; 13:2471.
51.
PolyakK, WeinbergRA. Transitions between epithelial and mesenchymal states: Acquisition of malignant and stem cell traits. Nat Rev Cancer, 2009; 9:265.
